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Abstract
Objective: Patients with a history of deliberate self-poisoning (DSP) are prescribed a greater amount of medication than the
general public. DSP is the most robust risk factor for repeat episodes of DSP and subsequent death by suicide, and one
might therefore expect that access to prescribed medication would be reduced following an episode of DSP. However, it is
unclear whether access to prescribed medication changes after an episode of DSP. The objectives of this study were to
investigate changes in 1) overall, psychotropic, non-psychotropic and the psychotropic subgroup antidepressant prescribed
medication availability in DSP patients following an episode of DSP, 2) prescribing of the medication ingested in the
episode, and 3) potential effects of gender, age and repeater status on such change.
Methods: The design was longitudinal. We included 171 patients admitted for DSP between January 2006 and March 2007.
Data on patients’ prescriptions prior to admission were retrieved from The Norwegian Prescription Database. The outcome
measure was the difference between medication load in the year following compared to the year prior to the DSP episode.
Results: There was a significant increase in total medication load following DSP, including both psychotropic and non-
psychotropic medication. Antidepressant medication load remained stable. There was a tendency for access to drugs
ingested in the episode to increase following the episode, albeit not significantly. Medication load increased with age across
all medication groups irrespective of time period and gender.
Conclusions: The findings show that physicians do not curb prescribing to patients who have recently deliberately self-
poisoned. Moreover, they highlight the need for cautious and judicious prescribing for these patients, in combination with
psychological and social interventions.
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Introduction
Approximately 90% of deliberate self-harm (DSH) episodes that
present to hospitals involve deliberate self-poisoning (DSP) [1].
Monitoring and limiting access to medication therefore is a pivotal
aspect of suicide prevention.
We have previously shown that patients with a history of DSP
are prescribed an excessive amount of medication compared to the
general public [2]. The majority of DSP patients use medication
prescribed to them in their episodes [2], particularly those
individuals who are severely depressed [3]. The much greater
medication load found for DSP patients is likely to reflect a high
degree of morbidity in this patient group [4–7]. In many cases,
periods of high suicide risk are extremely brief [8,9], thus access to
medication may be a critical factor in turning compelling suicidal
impulses to actual behaviour, including repeat episodes.
Little is known about what sort of treatment DSP patients
receive following DSP episodes. To our knowledge no studies have
explored whether and how prescribing to DSP patients changes
following an episode of DSP. This is the case both for overall
medication load, and in relation to specific drugs, such as
antidepressants or drugs ingested in the episode. Our previous
findings showed that it is the high medication load in general
rather than the timing of single prescriptions in relation to time of
episode that carries risk for deliberate self-poisoning [2]. Although
medical conditions in most cases are unlikely to change abruptly
following a DSP episode, the act itself may affect prescribing on an
individual level either by serving as a marker of underlying
problems not previously recognised by the prescriber(s), or by
alerting prescribers to hitherto unacknowledged risks associated
with on-going, long-term access to prescribed drugs. Moreover,
the finding that the majority of DSP patients used medication
prescribed to them in their DSP episodes [2] raises the question as
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to whether access to drugs ingested in the DSP episode changes
after a DSP episode. To our knowledge no studies have explored
whether and how prescribing to DSP patients changes following
an episode of DSP. This is the case both for overall medication
load and in relation to specific drugs, such as antidepressants or
drugs ingested in the episode.
The objectives of this study were to investigate changes in 1)
overall, psychotropic, non-psychotropic and antidepressant pre-
scribed medication availability in DSP patients after compared
with before an episode of DSP, 2) changes in prescribing of the
medication ingested in the episode, and 3) potential effects of
gender, age and repeater status on such change.
Materials and Methods
Design
Differences in medication load in the year following DSP
episodes compared with the year beforehand were investigated in
a longitudinal design comprising questionnaire as well as registry
data for patients admitted to hospital for an episode of DSP.
Data collection
DSP was defined as the intentional self-administration of more
than the prescribed or recommended dose of any medication and
with evidence that the act was intended to harm the patient
though not necessarily to result in death [10]. The patients
included in the study were individuals aged 18 years or older who
had engaged in DSP and had presented to three major hospitals in
Eastern Norway, Ulleva˚l University Hospital, Oslo, Innlandet
Hospital Trust, Gjøvik and Vestre Viken Hospital Trust, Bærum,
between January 2006 and March 2007. These are all somatic
hospitals, treating most cases of DSP. Patients treated without
admission or referred directly from outpatient units, i.e., GP or
psychiatric outpatient clinics, to psychiatric wards were not
included in the study. Patients who were intellectually or
developmentally disabled, psychotic or non-Norwegian speaking
were excluded, as were patients admitted for accidental medica-
tion overdoses. The medical staff at the hospitals recruited the
DSP cases to participate in the study while they were hospitalised
(t1). Each patient completed a questionnaire, with the majority
completing within the day following hospital presentation. Trained
health personnel assisted the patients in completing the question-
naire.
Measures
Prescription registry data. The outcome measure was
difference between medication load in the year following
compared to the year prior to the DSP episode. Data on patients’
prescription records were retrieved from The Norwegian pre-
scription database (NorPD) based on the patients’ personal
identification numbers.
By medication load we refer to the total amount of prescribed
medication collected by an individual over a specified period of
time. This may refer to medication load overall, or for subgroups,
i.e., psychotropic and non-psychotropic medication. The mea-
surement unit defined daily dose (DDD) is defined as the assumed
average maintenance dose per day for a drug used for its main
indication in adults (WHO Collaborating Centre for Drug
Statistics Methodology). Drugs were described according to the
Anatomical Therapeutic Chemical (ATC) classification system
[11]. All collected medication was included in the analyses.
Psychotropic drugs comprised antidepressants (ATC-code N06A),
neuroleptics (ATC-code N05A), sedatives (ATC-codes N05B and
N05C), anti-epileptics (ATC-code N03A), opioid analgesics (ATC-
code N02A), non-opioid analgesics (ATC-codes N02B and M01A)
and carisoprodol (ATC-code M03BA72). Albeit being classified as
a muscle relaxant, carisoprodol was included in the psychotropic
subgroup due to its frequent use in DSP [12].
Questionnaire data. In the current study, the following
information from the patient self-report questionnaires was used:
age, gender, repeater status at the time of the index episode (t1),
i.e., whether the DSP episode that included them in the study was
a repeat episode for that individual or a first-ever incident, and
repeater status at t3, i.e., whether patients had made repeat
episodes at 12 months follow-up. Patients also completed the Beck
Depression Inventory Short Form (BDI-SF), a 13 items measure of
level of depression [13].
Hospital data. Medication ingested in DSP episodes was
identified by a physician who conducted a clinical evaluation of
the medication involved based partly on clinical judgment and
information from the patient, and partly on laboratory findings,
(i.e., blood analyses) where necessary.
Statistical analyses
Pre- and post-episode differences in collection of prescribed
medication and potential effects of age, gender and repeater status
were tested by fitting multilevel models using MLwiN version 2.24.
The analysis took into account fact that the data are nested, i.e.,
dependency between various observations (i.e. collections) deriving
from the same individual. The variance of the total DDD depends
on the number of collections and this was taken into account by
weighting according to that number. Model fit, i.e., normality of
model residuals, was assessed using diagnostic plots supplemented
by the Shapiro-Wilk normality test. All of the percentage increases
quoted were obtained for the median patient age.
Ethics
The study was approved by the East Regional Ethics
Committee, the Privacy Ombudsman for Research as well as
the Data Inspectorate. Written informed consent was obtained
from all participating patients prior to inclusion in the study.
Results
The whole sample was included in analyses regarding medica-
tion availability. Because only one hospital could provide data on
drugs ingested in the DSP episode, only patients from this hospital
were included in analyses regarding changes in collections of drugs
ingested in the episode in the year following t1 compared to the
year prior to the DSP episode.
All 286 eligible DSP patients treated for 378 DSP episodes
during the study period were identified consecutively. Of the 286
patients, 177 (67.8% female and 32.2 male) consented to the
researcher having access to information about prescriptions
collected by them, yielding a 61.9% total response rate for registry
data. For three patients, matching with registry data was not
possible, for another three the method of self-harm did not involve
DSP, yielding a sample of 171 patients for which registry data
were obtained. In analyses regarding repeater status and
depression level at t1, the number of patients included in the
analyses were reduced to n = 128 due to missing values on these
measures. Attrition analyses showed no gender differences
between participating patients and those who declined to
participate (p = 0.5), whereas older age predicted attrition (mean
age in sample 38.6 years (Sd = 14.7) versus 43.7 years (Sd = 19.4)
in non-participants, p = 0.02). We conducted a Wilcoxon signed
rank test to investigate whether age and gender were confounded.
Medication Load following DSP
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Median age for males were significantly higher than for females
(42 vs 35 yrs, respectively, p = 0.01).
Of the 117 eligible patients from the hospital where information
was available on medication used for DSP, 85 patients consented
to access to information about prescriptions dispensed to them,
yielding a 72.6% response rate for registry data. After excluding
one patient for whom matching with registry data was not possible
there were 84 patients for whom registry data were obtained. The
mean age of the patients was 37 years (SD = 14.8), which did not
differ significantly from the mean age of participants from the two
other hospitals (p = 0.2). The Shapiro Wilk normality test was used
to confirm the validity of the normality assumptions for all the
fitted models.
1. Total medication load from year before to year after
the DSP episode
We took account of the repeated measures on each patient by
fitting a multilevel model and included explanatory variables that
may influence change in medication load from before to after a
DSP episode (i.e., age, gender, depression at t1, repeater status at
t1). Total medication load increased significantly in the year after
the episode compared to beforehand (p,0.01). Females collected
significantly more medication overall irrespective of age and time
period (p = 0.01). Moreover, as shown in Fig. 1A, they also
collected significantly more medication in the year after compared
to the year prior to the episode (p,0.01), with the increase in
DDD collected amounting to 21.2%. As shown in Fig. 1B, there
was no significant pre-post difference for males. Total medication
load increased with age irrespective of time period (p,0.01). This
increase was not associated with depression level at t1 (p = 0.82).
However, a significant interaction between gender and depression
was found in that females collected more medication on the whole,
irrespective of time period and age, compared to males with equal
depression level. Repeater status at t1 had no bearing on the pre-
post change in total medication load. Although the pre-post
change was positive for all age groups, the pre-post difference for
females increased gradually with age, as shown in Fig. 1A.
2. Psychotropic and non-psychotropic medication load
In order to delineate potential pre-post differences in psycho-
tropic and non-psychotropic medication load, models were fitted
separately for these two subgroups.
Psychotropic medication load. As with total medication
load, psychotropic medication load increased significantly in the
year after compared to the year prior to the episode (p = 0.04).
Whereas depression level at t1 was associated with the overall level
of psychotropic medication (p,0.01), there was no effect of
depression level at t1 on the pre-post change in psychotropic
medication load (p = 0.15). Figure 2 shows psychotropic medica-
tion load year before and after the episode for females (2A) and
males (2B), respectively, by age. Psychotropic medication load
increased with age irrespective of time period and gender (p,
0.01), and peaked in the 50–70 age bracket. There was no
significant difference between males’ and females’ psychotropic
medication load (p = 0.27).
Antidepressants medication load. We then investigated
whether the psychotropic subgroup antidepressants showed a
similar pattern to psychotropic drugs in general. There was no
significant, demonstrable pre-post increase in antidepressant
medication load (p = 0.42), and the total amount collected was
not significantly different for males and females overall (p = 0.69).
The pre-post increase in DDD collected was 9.7% for males and
9.4% for females, respectively, but this increase was not significant.
There was no significant increase in any of the antidepressant
subgroups tricyclic antidepressants, Selective Serotonin Reuptake
Inhibitors (SSRIs), and others. Thus, there was no tendency for
prescribers to replace the more toxic tricyclic subgroup with the
less toxic SSRIs. However, antidepressant load increased with age
irrespective of time period and gender (p,0.01).
Non-psychotropic medication load. Figure 3 shows non-
psychotropic medication load in the year before and year after the
episode by age and gender (A: females, B: males). There was a
significant increase in non-psychotropic medication load in the
year after the episode (p,0.01) compared to the year prior to the
DSP episode amounting to 24.3% increase in DDD collected).
This increase was not dependent on gender (p = 0.53). Non-
Figure 1. One year medication load by age and gender. Total medication load increased significantly in the year following the episode
compared to beforehand (p,0.01). Figure 1A displays one year total medication load (DDD) for females by age before and after the episode, with the
means (solid lines) and standard error envelopes (dashed lines). Females collected significantly more medication in the year after compared to the
year prior to the episode (p,0.01), with the increase in DDD collected amounting to 21.2%. The pre-post difference for females gradually increased
with age. There was no significant pre-post difference for males.
doi:10.1371/journal.pone.0098086.g001
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psychotropic medication load increased with age (p,0.01), and
females collected more non-psychotropic overall irrespective of
age and time period (p = 0.01). There was no significant
interaction effect between gender and age.
3. Changes in medication load for drugs ingested in the
episode
For the subgroup of patients who ingested prescribed drugs in
the episode (n = 60), we investigated whether the medication load
of these drugs changed from before to after the episode by fitting a
multilevel model including gender, age and time period. There
was a tendency for collections of medication ingested in the
episode to increase following the episode, however this trend was
not significant (p = 0.09). Females collected more drugs used in the
DSP episode compared to men, irrespective of time period and age
(p = 0.01), and as with the other categories of medication, this
medication load increased with age irrespective of gender and time
period (p,0.01). Neither depression level at t1 or repeater status at
t1 was associated with changes in this medication load from the
year before to the year after the episode.
4. Accumulation year following compared to the year
prior to the DSP episode
Comparison of year prior to and following the episode is
potentially inaccurate as patients may be prescribed medication at
different times in the two years, i.e., we may not be comparing the
Figure 2. One year psychotropic load by age and gender. Figure 2A displays one year psychotropic medication load before and after the
episode for females with the means (solid lines) and standard error envelopes (dashed lines). Psychotropic medication load increased significantly in
the year after compared to the year prior to the episode (p = 0.04). Psychotropic medication load increased with age irrespective of time period and
gender (p,0.01), and peaked in the 50–70 age bracket. There was no significant difference between males’ and females’ psychotropic medication
load (p = 0.27).
doi:10.1371/journal.pone.0098086.g002
Figure 3. One year non-psychotropic load by age and gender. Figure 3A displays one year non-psychotropic medication load before and
after the episode for females, and Figure 3B displays the corresponding information for males. Solid lines represent the means with dashed lines
showing standard error envelopes. There was a significant increase in non-psychotropic medication load in the year after the episode (p,0.01)
compared to the year prior to the DSP episode (a 24.3% increase in DDD collected), but this increase was not dependent on gender (p = 0.53). Non-
psychotropic medication load increased with age (p,0.01), and females collected more non-psychotropic overall irrespective of age and time period
(p = 0.01).
doi:10.1371/journal.pone.0098086.g003
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same time periods. We therefore investigated whether they were
accumulating at the same rate in the two years. Figure 4 depicts
the accumulated (total) DDD collected over the year prior to and
the year following the episode, broken down into quarters and
reported for non-psychotropic, psychotropic, and antidepressants
within each quarter. The pace with which patients accumulated
prescribed medication was steady over the two years, although the
increase was faster over the first three months following the
episode compared to the corresponding period in the year
preceding it.
Discussion
We have previously reported the considerable medication load
of DSP patients compared to the general public for the time
leading up to the DSP episode [2]. Here we have investigated
whether medication load changes in the year following the episode
compared to the year beforehand. Our findings show that the
amount of drugs collected increased significantly in the year
following the episode compared to the year prior to the DSP
episode.
Pre-post change in total, psychotropic and non-
psychotropic medication load
The pre-post increase for total medication load is perhaps not
surprising given that the index DSP episode may have served to
alert patients’ general practitioners about hitherto unacknowl-
edged mental health problems. However, the increase was not
driven by an increase in psychotropic medication load alone: both
types of medication increased. This is surprising, given that the
level of physical morbidity in the sample is likely to remain
relatively stable from one year to the next. Indeed, given that the
majority of patients were in the younger age groups, it is unlikely
that the increase can be accounted for by an increase in chronic
physical disorders warranting medical treatment. However, we
cannot rule out entirely the possibility that an increased morbidity
in the sample around the period of the DSP episode, due to the
one year increase in age from pre to post episode, have contributed
to this increase.
It is possible that an adverse outcome such as a DSP episode
prompted prescribers, in most cases, the general practitioner, to
increase both frequency and quality of consultations. Increased
and improved follow-up by prescribers may influence the total
medication load in at least two ways: First, the attention of
physicians to both physical and mental problems may be
increased, with consequent increased prescribing including of
new drugs. Second, previous studies have shown a strong
association between suicidality and chronic physical conditions,
and it has been suggested that this association is mediated in part
by the hopelessness perceived in relation to the physical problems
[14]. Hopelessness about physical conditions increases the risk of
non-compliance, and polypharmacy, i.e., the use of several types
of medication at the same time, has consistently been found to
reduce overall compliance [15]. Thus the post-episodic rise in non-
psychotropic medication load may in part reflect that prescriptions
and collections become more aligned as a consequence of
improved frequency and quality of health care follow-up. As
such, the DSP episode may paradoxically serve to enhance the
quality of medical health care provided.
The consistent increase in medication load with age is in
keeping with the observed polypharmacy in the older population
at large [15,16] and the comparatively extensive use of opioids
among the elderly [17], reflecting in part increased morbidity with
age. Whilst no doubt motivated by and in many cases helpful in
patients with high comorbidity, other non-medical factors
contributing to polypharmacy, e.g., doctor-patient interaction,
are less well understood. In patients vulnerable to DSP and thus to
the toxic potential in polypharmacy these factors warrant
particular attention.
The finding that females consistently collect more overall is in
keeping with the tendency for females to collect more prescriptions
overall in the population at large. Interestingly, however, there was
no marked gender difference in psychotropic medication load.
This is contrary to what has been found in a recent population-
based study of psychotropic drug use [18]. One possible reason for
this discrepancy is that all patients in our study had engaged in
suicidal behaviour and thus potentially represent a subgroup
within which gender differences are less pronounced than in the
population at large. This warrants further study.
The pre-post increase in psychotropic medication is less
surprising. Not only may the episode have served as an indicator
of underlying mental illness not previously recognised – the
episode may also have served as an indicator that current medical
treatment for mental problems warranted adjustment, i.e., the pre-
post psychotropic increase may reflect a recognition of under-
prescribing of psychotropic medication. Due to the strong
association between suicidal behaviour and depression, this would
have been likely to be seen in the antidepressant subgroup.
However, the antidepressant medication load was relatively stable,
possibly reflecting that these patients were already prescribed
antidepressants. It is likely that some of the mechanisms suggested
to explain the pre-post increase in non-psychotropic medication,
such as increased quality and frequency of follow-up; or increased
compliance, are at play for psychotropic prescribing as well.
Figure 4. DDD per quarter year before and year after the
episode by medication group, cumulating quarterly within
each year. Comparison of year prior to and following the episode is
potentially inaccurate as patients may be prescribed medication at
different times in the two years, i.e., we may not be comparing the
same time periods. We therefore investigated whether they were
accumulating at the same rate in the two years. Figure 4 depicts the
accumulated (total) DDD collected over the year prior to and the year
following the episode, broken down into quarters and reported for non-
psychotropic, psychotropic, and antidepressants within each quarter.
The pace with which patients accumulated prescribed medication was
steady over the two years, although the increase was faster over the
first three months following the episode compared to the year
preceding it.
doi:10.1371/journal.pone.0098086.g004
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Strengths and limitations of this study
A main strength of the present study is that it is based on a
precise measure of access to prescription-based medication at an
individual level. In contrast to other studies the data have been
analysed longitudinally, thus enabling us to investigate the changes
in access to prescribed medication following an episode of DSP.
Moreover, the application of multilevel modelling ensures that the
nested nature of the data was taken into account. Furthermore,
medication ingested at the time of the DSP episode was evaluated
consecutively by a physician. Finally, rather than using data of
what was prescribed, we have looked at what types of medication
were actually collected and hence available. However, the study
has several limitations. First, the current data do not exclude the
possibility that the pre-post increase observed reflects a time trend
due to factors other than the DSP episode. To ascertain this would
require longer periods of observation. Whilst outside the scope of
this study this is undoubtedly a topic for further research.
Secondly, while it includes patients presenting to three hospitals,
analyses of pre-post differences in episodic medication load are
based on patients from one hospital. Thirdly, analyses of
prescriptions taken in overdose do not include OTC medication.
Fourthly, selection bias might limit the generalizability of the
findings. Because only patients who were admitted to hospital for
their DSP were included, the findings cannot be generalized to less
severe cases of DSP that are not admitted, which are relatively few,
nor other types of deliberate self-harm. Moreover, the non-
significant finding for changes in medication load for drugs
ingested in the episode may reflect an insufficient sample size, and
warrant further study. Finally, the higher mean age among persons
declining to participate might indicate a more ‘chronic’ sample.
However, our data did not suggest this.
Conclusions
The increased prescribing of drugs in the year following the
DSP episode shows that physicians do not curb prescribing to
patients who have recently deliberately self-poisoned. Given the
well-founded risks related to availability of means of suicide [19],
findings of this study highlight the need for cautious and judicious
prescribing for these patients, involving prescribing lowest effective
dose on a more frequent basis, in combination with psychological
and social interventions [20].
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